Insider buying last 90 days
No open-market insider purchases were filed for HLN in the last 90 days.
From Form 4 filings, dated to when each was filed.
Haleon's third-quarter organic revenue growth came in below expectations this week, with weak cold and flu consumption and a China supply disruption cited as drags, tightening the near-term growth outlook. Shares fell 2.39% on 9 November, closing at £3.31 and underperforming a rising FTSE 100 Index, and the stock now sits well below its 52-week high of £4.34 reached on 15 October. Separately, Haleon disclosed purchases of 11,006,678 ordinary shares under its buyback program, held as treasury shares, with transactions occurring between 9 and 13 November.
HLN closed at $9.20, up 0.3%, but remains below both its 50-day average of $9.33 and 200-day average of $9.70, with the 50-day also below the 200-day. The stock is down 9.2% over one month, 5.3% over three months, and 7.1% over one year, though up 0.3% over six months. The GekkoIndex reads 59.5, placing it in the Neutral zone, down from a prior reading of -3.1 over five days. Fair value sits at $12.58, putting the current price 26.9% below that mark.
The next earnings date is 4 March 2027, 107 days out and beyond a typical 20-trading-day hold. No insider, Congress, or unusual options activity appears in their respective windows. Seasonality from this point in the calendar has averaged a 6.9% gain over the next 20 trading days across 4 years, rising in 4 of them. Consensus analyst target stands at $10.40, implying 13% upside.
Written by AI from the Nov 16, 2026 close and checked automatically against the figures on this page.
Haleon scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed1 headwind
Below 50 and 200-day
Close $9.20 is below the 50-day ($9.33) and 200-day ($9.70) averages, and the 50-day is below the 200-day.
See the chart59.5, Neutral
Reading 59.5 is in the Neutral zone.
See the GekkoIndex25.0% below
Price is 25% below Gekko Fair Value (more than 5% below).
See fair valueNo data
No insider, Congress or unusual options activity in the window.
See smart moneyReports in 107 days
Next report Mar 4, 2027, 107 days away — outside a typical 20-trading-day hold.
See earnings+3.6% on average
From this point in the calendar, the next 20 trading days averaged +3.6% over 4 years, rising in 3 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Haleon closed at $9.20 on Nov 16, 2026, −7.1% over the past year, inside a 52-week range of $8.38 to $11.28.
Use the left and right arrow keys to read daily values.
Put HLN on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Haleon develops, manufactures, and distributes consumer wellness products, covering everything from early research through to getting finished goods onto shelves around the world. Its offerings span oral care, pain relief, respiratory support, and digestive health, along with vitamins, minerals, and other supplements. Among its recognizable names are Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum.
The business operates on an integrated model, running the full chain from scientific development to production and distribution rather than outsourcing these stages separately. Its goods reach consumers across North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific region, giving it a broad geographic footprint in the markets it serves.
Haleon traces its origins to 2021, when it was formed under the name DRVW 2022 plc before adopting its current name, Haleon plc, in February 2022. The company is headquartered in Brentford, in the United Kingdom, and its shares trade under the ticker HLN.
Haleon’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 59.5, in the Neutral zone, down 3.1 points over five sessions.
Down 3.1 points over five sessions, from the Accumulation zone.
Reading for Nov 16, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 34 | +1.0% | +2.5% | ||
| Accumulation | 211 | 0.0% | +0.5% | ||
| Neutral (current zone) | 371 | +0.1% | +0.7% | ||
| Distribution | 44 | +0.3% | −1.0% | ||
| Selling | 0 | Not available | |||
Average HLN share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
Haleon trades 25.0% below Gekko Fair Value of $12.26, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Haleon shares are worth, recalculated every trading day.
$12.26
Gekko Fair Value, Nov 17, 2026
25.0% Undervalued
At the end of Aug 2026 the price was 29.6% below the estimate.
No open-market insider purchases were filed for Haleon, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for HLN in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in HLN were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Haleon reports on Mar 4, 2027, before the open (107 days away), and beat the EPS estimate in 4 of its last 8 reports.
Mar 4, 2027
Expected before the open, 107 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Jul 30, 2026 | $0.28 est $0.27 | $7.52B est $6.40B | −4.0% |
| Apr 29, 2026 | $0.00 est $0.12 | — | −2.4% |
| Feb 25, 2026 | $0.26 est $0.25 | $7.51B est $7.57B | −2.9% |
| Oct 30, 2025 | $0.14 est $0.24 | $7.52B est $2.76B | +2.4% |
| Jul 31, 2025 | $0.24 est $0.24 | $7.25B est $7.48B | +0.2% |
| Apr 30, 2025 | $0.13 est $0.00 | — | +0.5% |
| Feb 27, 2025 | $0.05 est $25.25 | $7.14B est $2.74B | −0.2% |
| Oct 31, 2024 | $0.14 est $0.11 | $6.93B est $11.04B | −0.7% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Haleon is $10.40, +13.0% from the last close.
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 17, Haleon averaged +3.6% across the last 4 years, rising in 3 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +2.3% | 3 of 4 |
| Next 10 trading days | +2.5% | 3 of 4 |
| Next 15 trading days | +2.8% | 2 of 4 |
| Next 20 trading days | +3.6% | 3 of 4 |
| Next 30 trading days | +5.7% | 4 of 4 |
For scale, HLN’s typical 20-trading-day move in either direction is about 4.1%.
Haleon’s market cap is $40.38B, with a P/E ratio of 18.7 and revenue of $11.15B over the last twelve months.
Coverage of Haleon this week reads negative: 1 positive, 0 neutral and 2 negative headlines.
Haleon’s market cap is $40.38B at the Nov 16, 2026 close of $9.20, with 4.39B shares outstanding. The shares trade on a P/E ratio of 18.7.
The consensus analyst 12-month price target for Haleon is $10.40, +13.0% from the last close. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Haleon is undervalued: the Nov 16, 2026 close of $9.20 is 25.0% below Gekko Fair Value of $12.26. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Haleon is expected to report on Mar 4, 2027, before the market opens (107 days away). Analysts expect earnings of $0.28 per share on revenue of $7.58B. Haleon beat the earnings estimate in 4 of its last 8 reports, moving 1.7% on average across the report.
Haleon’s 52-week high is $11.28 and its 52-week low is $8.38; it closed at $9.20 on Nov 16, 2026, −7.1% over the past year. Over the last five years the shares peaked at $11.42 on Jun 2, 2025.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (fair value, earnings risk and seasonality), 1 as mixed (gekkoindex) and 1 as a headwind (trend). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,476 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.